NZSE:TRU

Stock Analysis Report

Executive Summary

TruScreen Limited, together with its subsidiaries, develops, manufactures, and sells cancer detection devices and systems in New Zealand.

Risk Analysis

Earnings have declined by -26.41% per year over past 5 years

Has less than 1 year of cash runway

Currently unprofitable and not forecast to become profitable over the next 3 years

Shareholders have been diluted in the past year

+ 2 more risks


Snowflake Analysis

Adequate balance sheet and overvalued.

Share Price & News

How has TruScreen's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: TRU has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

3.1%

TRU

-1.0%

NZ Medical Equipment

0.3%

NZ Market


1 Year Return

-36.1%

TRU

54.6%

NZ Medical Equipment

21.9%

NZ Market

Return vs Industry: TRU underperformed the NZ Medical Equipment industry which returned 51.4% over the past year.

Return vs Market: TRU underperformed the NZ Market which returned 21.1% over the past year.


Shareholder returns

TRUIndustryMarket
7 Day3.1%-1.0%0.3%
30 Day-12.2%2.7%-0.2%
90 Day0%10.3%7.2%
1 Year-36.1%-36.1%57.2%54.6%26.9%21.9%
3 Year-27.9%-27.9%109.3%99.7%60.1%39.2%
5 Year-25.2%-25.2%165.9%143.9%98.3%54.2%

Price Volatility Vs. Market

How volatile is TruScreen's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is TruScreen undervalued compared to its fair value and its price relative to the market?

1.99x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate TRU's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate TRU's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: TRU is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.

PE vs Market: TRU is unprofitable, so we can't compare its PE Ratio to the NZ market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate TRU's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: TRU is good value based on its PB Ratio (2x) compared to the XO Medical Equipment industry average (5.5x).


Next Steps

Future Growth

How is TruScreen forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

17.5%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as TruScreen has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has TruScreen performed over the past 5 years?

-26.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: TRU is currently unprofitable.

Growing Profit Margin: TRU is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: TRU is unprofitable, and losses have increased over the past 5 years at a rate of -26.4% per year.

Accelerating Growth: Unable to compare TRU's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: TRU is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (12.8%).


Return on Equity

High ROE: TRU has a negative Return on Equity (-25.72%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is TruScreen's financial position?


Financial Position Analysis

Short Term Liabilities: TRU's short term assets (NZ$4.5M) exceed its short term liabilities (NZ$1.4M).

Long Term Liabilities: TRU's short term assets (NZ$4.5M) exceed its long term liabilities (NZ$57.5K).


Debt to Equity History and Analysis

Debt Level: TRU's debt to equity ratio (5.4%) is considered satisfactory.

Reducing Debt: TRU's debt to equity ratio has reduced from 5.8% to 5.4% over the past 5 years.


Balance Sheet

Inventory Level: TRU has a low level of unsold assets or inventory.

Debt Coverage by Assets: TRU's debt is covered by short term assets (assets are 7.3x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: TRU has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: TRU has less than a year of cash runway if free cash flow continues to reduce at historical rates of -12.7% each year


Next Steps

Dividend

What is TruScreen's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%2.9%markettop25%5.5%industryaverage1.3%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate TRU's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate TRU's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if TRU's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if TRU's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of TRU's dividend in 3 years as they are not forecast to pay a notable one for the NZ market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.6yrs

Average management tenure


CEO

Tony Ho (61yo)

NZ$33,564

Compensation

Mr. Anthony Peng Ho, also known as Tony, B.Comm, CA, FAICD, FCIS, FGIA, serves as the Chairman and Interim Chief Executive Officer at TruScreen Limited. He has been an Executive Director of Newfield Resour ...


Leadership Team

NamePositionTenureCompensationOwnership
Anthony Ho
Chairman & Interim CEO0yrsNZ$33.56k0.62% NZ$141.4k
Guy Robertson
CFO & Company Secretary1.3yrsno data0.045% NZ$10.3k
Paul Curran
General Manager of Operations1.6yrsno datano data
Nicole Melia
Manager of Administration1.8yrsno datano data
. Phunc
Head of Cancer Department0yrsno datano data
. Chuong
Head of Research & Development and Training Department0yrsno datano data
. Thuy
Head of High Service Gynaecology Examination0yrsno datano data

1.6yrs

Average Tenure

Experienced Management: TRU's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Anthony Ho
Chairman & Interim CEO0yrsNZ$33.56k0.62% NZ$141.4k
Neville Hacker
Chairman of Medical Advisory Board0yrsno datano data
Christopher Horn
Independent Director6.3yrsNZ$40.00k0.68% NZ$156.5k
Michael Campion
Member of Medical Advisory Board0yrsno datano data
Ronald Jones
Non-Executive Director & Member of Medical Advisory Board2.3yrsNZ$56.70kno data
Christopher Lawrence
Non-Executive Director2.2yrsNZ$40.00k8.79% NZ$2.0m
Con Hickey
Non-Executive Director1.5yrsNZ$25.15kno data
William Hunter
Alternate Director1.3yrsno data0.12% NZ$26.5k

1.8yrs

Average Tenure

Experienced Board: TRU's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: TRU insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 18.8%.


Top Shareholders

Company Information

TruScreen Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: TruScreen Limited
  • Ticker: TRU
  • Exchange: NZSE
  • Founded: 2013
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: NZ$22.981m
  • Shares outstanding: 227.53m
  • Website: https://www.truscreen.com

Location

  • TruScreen Limited
  • Equitable House
  • Level 6
  • Auckland
  • 1010
  • New Zealand

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
TRUNZSE (New Zealand Stock Exchange)YesOrdinary SharesNZNZDNov 2014

Biography

TruScreen Limited, together with its subsidiaries, develops, manufactures, and sells cancer detection devices and systems in New Zealand. The company offers the TruScreen cervical cancer screening system, a medical device for detecting the presence of precancerous and cancerous tissue on the cervix in real time. It also distributes products in China, Russia, Zimbabwe, Mexico, Papua New Guinea, and internationally. TruScreen Limited was incorporated in 2013 and is headquartered in Auckland, New Zealand. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/18 10:48
End of Day Share Price2020/02/18 00:00
Earnings2019/09/30
Annual Earnings2019/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.